(Circulation. 2004;110:e27-e31.)
© 2004 American Heart Association, Inc.
Clinician Update |
From the Department of Cardiology, Ochsner Clinic Foundation, New Orleans, La.
Correspondence to Richard V. Milani, MD, Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121. E-mail rmilani{at}ochsner.org
| Introduction |
|---|
|
|
|---|
What is the primary cause of his dyspnea? Is it ventilatory or circulatory? Obesity or deconditioning? What is the prognosis for his ischemic cardiomyopathy? What would be the appropriate diagnostic study to obtain these answers?
| Background |
|---|
|
|
|---|
A major function of the cardiovascular system is gas exchange, supplying O2 and other fuels to working muscles, as well as removal of CO2 and other metabolites. The heart, lungs, and pulmonary and systemic circulations form a single circuit for exchange of respiratory gases between the environment and the cells of the body.1,2 Under steady-state conditions, respiratory oxygen uptake (
O2) and carbon dioxide outflow (
CO2) measured at the mouth are equivalent to oxygen utilization (
O2) and carbon dioxide production (
CO2) occurring in the cell, thus "external respiration" equals "internal respiration." CPX directly measures
O2,
CO2, and air flow (minute ventilation [
E], tidal volume, and respiratory rate) on a breath-by-breath basis using a nonrebreathing valve connected to a metabolic cart. Samples of expired air are typically assessed every 15 seconds, and real-time data are expressed in both a tabular and graphic format. Additionally, oxygen saturation using finger or ear oximetry is monitored and recorded. From these data, numerous clinically relevant metabolic parameters can be derived (Table 1). The abbreviations used subsequently are explained in Table 1.
|
| Metabolic Derangements in Disease |
|---|
|
|
|---|
|
|
CPX provides an ideal modality for the evaluation of patients presenting with exertional dyspnea and fatigue, at which time the clinician is faced with a breadth of differential diagnoses ranging from circulatory impairment to deconditioning. Standard diagnostic studies may not identify the true cause because circulatory and ventilatory reserves cannot be assessed from indices of resting cardiac and pulmonary function.3 By virtue of obtaining gas exchange data under the provocation of exercise, CPX can discriminate among many subtle and often overlapping etiologies.
Etiology of Dyspnea
Using the algorithm provided in Figure 2, a peak oxygen uptake (Pk
O2) <85% of that predicted by age and gender is considered to be low, and a normal anaerobic threshold (AT) is generally closer to 60% of the predicted Pk
O2. For purposes of classification, an AT <40% of the predicted peak
O2 is considered pathologically reduced and indicative of circulatory insufficiency. A breathing reserve (BR) <30% would indicate ventilatory impairment, especially when accompanied by oxygen desaturation with exercise, although a BR of 20% to 30% is deemed a borderline value. CPX is very useful in dyspneic patients with combined cardiac and pulmonary diseases who may have a reduction in both AT and BR, the more dominant of which may indicate the primary cause of the patients functional limitation. A respiratory exchange ratio (RER) of <1.1 (particularly <1.0) in the absence of other metabolic abnormalities suggests poor effort, anxiety, or mild disease. Finally, this type of evaluation can be helpful in patients being evaluated for employment disability.
|
Heart Failure Prognosis
From a clinical standpoint, probably the greatest utilization of CPX has been in the evaluation of patients with advanced systolic heart failure, in which CPX has gained widespread use by virtue of its superior prognostic capabilities in these patients. In the Veterans Administration Heart Failure Trial (V-HeFT), the mortality rate of patients with a
O2max
14.5 mL/kg per minute was double that of patients whose
O2max exceeded this value, a finding more significant than the drug treatment effect being studied.4 In a separate investigation of heart failure patients referred for cardiac transplantation, Mancini et al5 found that Pk
O2 was the single best predictor of survival. Moreover, transplantation could be safely deferred in patients whose Pk
O2 was >14 mL/kg per minute, where their survival exceeded that of patients undergoing heart transplantation. As a result of these seminal studies, CPX remains a pivotal modality in initial evaluation of patients with advanced heart failure, especially those who are considered for heart transplantation. The commonly used Weber-Janicki classification of exercise capacity in heart failure is provided in Table 3.6
|
Although a Pk
O2 cutoff of 14 mL/kg per minute remains an important prognostic discriminator in heart failure patients, our laboratory and others have described disparities in its prognostic utility when evaluating patients with intermediate levels of Pk
O2 (between 10 and 18 mL/kg per minute) as well as in special populations such as women and obese patients.79 Investigators have therefore sought to evaluate the predictive strength of other metabolic parameters in advanced heart failure, including percent predicted Pk
O2,10 ventilation/carbon dioxide production ratio and slope,11 oxygen consumption recovery,12 and O2 pulse.13,14 Each investigation demonstrated variability with regard to each parameters predictive strength. Moreover, a recent investigation suggests that the widespread use of ß-blocker therapy in heart failure may require alteration of the Pk
O2 cutoff point of 14 mL/kg per minute to a lower value.15
A fundamental understanding of O2 consumption may explain the disparate observations in women and obese patients. Although Pk
O2 is corrected for total body weight, body fat is "metabolically inert," consuming essentially no oxygen, and can represent a significant portion of total weight. Moreover, considerable variability in body composition is present across populations, including those with heart failure. We demonstrated that correcting Pk
O2 for lean body mass (Pk
O2lean) provides a more refined discriminator of outcome than traditionally reported total weightadjusted values.16 In heart failure patients, a Pk
O2lean cutoff of 19 mL/kg per minute provides a more robust discriminator than the total weightadjusted figure of 14 mL/kg per minute. As such, we routinely assess body fat using the 3-site skinfold method before each CPX study to calculate lean body mass.17 From a practical standpoint, this adds only 3 to 4 minutes to the time required to perform a CPX. Using the lean adjusted peak oxygen uptake, we eliminated previously observed disparities between genders, and between obese and nonobese patients, in predicting outcome in heart failure. We also reported the usefulness of peak O2 pulse (cutoff value 10 mL/beat), especially when corrected for lean body mass (cutoff value 14 mL/beat), in predicting prognosis in patients with chronic systolic heart failure.18
Less commonly, clinicians need to evaluate heart failure patients who have very limited exercise tolerance resulting from low threshold angina or severe ventricular arrhythmias, in which an early exercise surrogate of Pk
O2 would be required for risk stratification. Our laboratory and others successfully used the pattern of
E/
CO2 change during early exercise to predict Pk
O2 and subsequent outcome in such patients.11,19,20 We found that a decrease in
E/
CO2 of <10% early in exercise predicts a Pk
O2 of <14 mL/kg per minute and poor outcome in patients with heart failure.
| Pitfalls in CPX Interpretation |
|---|
|
|
|---|
O2 is now a commonly used end point in various clinical investigations, particularly heart failure trials.2123 Changes in Pk
O2, therefore, may have important prognostic and therapeutic consequences.24,25 An increase in Pk
O2 by as little as 1 mL/kg per minute can mean as much as a 69-second gain in treadmill exercise time, as well as improved cardiovascular outcomes.24,26 In this context, however, it is important to remember that several factors, including effort, can influence the Pk
O2 value. Consequently, Pk
O2 may not always be the appropriate metabolic end point to evaluate the effects of a given intervention (Figure 3). Because Pk
O2 can be effort dependent, Pina and Karalis27 demonstrated that AT rather than Pk
O2 was a more reproducible and effort-independent parameter in heart failure patients undergoing serial testing. Therefore, AT and knowledge of RER must accompany Pk
O2 data when making clinical decisions, particularly with regard to results of therapeutic interventions.28 In the less common event that AT is not achieved, an occurrence in up to 30% of our heart failure population, we successfully used the pattern of
E/
CO2 change in early exercise to predict Pk
O2 and subsequent outcomes in such patients.11,19,20
|
| Conclusions |
|---|
|
|
|---|
O2=19.2 mL/kg per minute (63% of predicted), measured metabolic equivalents =5.5
O2lean=30.33 mL/kg per minute (% body fat =36.7%)
On the basis of the interpretative schema in Figure 2, we conclude that this patient demonstrated an adequate effort (RER
1.1) with a low peak aerobic capacity (Pk
O2 63% of predicted). The AT was normal, suggesting adequate circulatory status. Additionally, the BR and O2 saturation at peak exercise were in the normal range, thereby excluding a ventilatory etiology to the patients symptoms. Despite the underlying presence of a cardiomyopathy, the most likely explanation for the patients symptoms is deconditioning, in large part due to the patients obesity. The cardiopulmonary data suggest a very favorable prognosis for his cardiomyopathy. The patients symptoms can be improved and possibly eliminated by enrollment into a structured conditioning program of exercise training.
| References |
|---|
|
|
|---|
2. Wasserman K, Hansen J, Sue D, Casaburi R, Whipp B. Principles of Exercise Testing and Interpretation. Philadelphia, Pa: Lea & Febiger; 1999.
3. Neuberg GW, Friedman SH, Weiss MB, Herman MV. Cardiopulmonary exercise testing: the clinical value of gas exchange data. Arch Intern Med. 1988; 148: 22212226.
4. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325: 303310.[Abstract]
5. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991; 83: 778786.
6. Weber KT, Kinasewitz GT, Janicki JS, Fishman AP. Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure. Circulation. 1982; 65: 12131223.
7. Richards DR, Mehra MR, Ventura HO, Lavie CJ, Smart FW, Stapleton DD, Milani RV. Usefulness of peak oxygen consumption in predicting outcome of heart failure in women versus men. Am J Cardiol. 1997; 80: 12361238.[CrossRef][Medline] [Order article via Infotrieve]
8. Lavie CJ, Milani R, Mehra MR, Ventura HO, Messerli FH. Obesity, weight reduction and survival in heart failure. J Am Coll Cardiol. 2002; 39: 1563; author reply 2002;39:15631564.
9. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol. 2003; 91: 891894.[CrossRef][Medline] [Order article via Infotrieve]
10. Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw LJ, Kargl D, Chaitman BR. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 1996; 27: 345352.[Abstract]
11. Milani RV, Mehra MR, Reddy TK, Lavie CJ, Ventura HO. Ventilation/carbon dioxide production ratio in early exercise predicts poor functional capacity in congestive heart failure. Heart. 1996; 76: 393396.
12. Robbins M, Francis G, Pashkow FJ, Snader CE, Hoercher K, Young JB, Lauer MS. Ventilatory and heart rate responses to exercise: better predictors of heart failure mortality than peak oxygen consumption. Circulation. 1999; 100: 24112417.
13. Cohen-Solal A, Barnier P, Pessione F, Seknadji P, Logeart D, Laperche T, Gourgon R. Comparison of the long-term prognostic value of peak exercise oxygen pulse and peak oxygen uptake in patients with chronic heart failure. Heart. 1997; 78: 572576.
14. Cohen-Solal A, Tabet JY, Logeart D, Bourgoin P, Tokmakova M, Dahan M. A non-invasively determined surrogate of cardiac power (circulatory power) at peak exercise is a powerful prognostic factor in chronic heart failure. Eur Heart J. 2002; 23: 806814.
15. Zugck C, Haunstetter A, Kruger C, Kell R, Schellberg D, Kubler W, Haass M. Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol. 2002; 39: 16151622.
16. Osman AF, Mehra MR, Lavie CJ, Nunez E, Milani RV. The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. J Am Coll Cardiol. 2000; 36: 21262131.
17. Jackson AS, Pollock ML. Practical assessment of body composition. Physician Sports Med. 1985; 13: 7690.
18. Lavie CJ, Milani RV, Mehra MR. Peak exercise oxygen pulse and prognosis in chronic heart failure. Am J Cardiol. 2004; 93: 588593.[CrossRef][Medline] [Order article via Infotrieve]
19. Kleber FX, Vietzke G, Wernecke KD, Bauer U, Opitz C, Wensel R, Sperfeld A, Glaser S. Impairment of ventilatory efficiency in heart failure: prognostic impact. Circulation. 2000; 101: 28032809.
20. Koike A, Itoh H, Kato M, Sawada H, Aizawa T, Fu LT, Watanabe H. Prognostic power of ventilatory responses during submaximal exercise in patients with chronic heart disease. Chest. 2002; 121: 15811588.
21. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003; 107: 294299.
22. Giannuzzi P, Temporelli PL, Corra U, Tavazzi L. Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) trial. Circulation. 2003; 108: 554559.
23. Jaski BE, Lingle RJ, Kim J, Branch KR, Goldsmith R, Johnson MR, Lahpor JR, Icenogle TB, Pina I, Adamson R, Favrot LK, Dembitsky WP. Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial. J Heart Lung Transplant. 1999; 18: 10311040.[CrossRef][Medline] [Order article via Infotrieve]
24. Grigioni F, Barbieri A, Magnani G, Potena L, Coccolo F, Boriani G, Specchia S, Carigi S, Musuraca A, Zannoli R, Magelli C, Branzi A. Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. Am Heart J. 2003; 146: 298303.[CrossRef][Medline] [Order article via Infotrieve]
25. Ventura HO, Mehra MR. Hippocrates and prognosis in heart failure: the challenge of static and dynamic measurements. Am Heart J. 2003; 146: 215217.[CrossRef][Medline] [Order article via Infotrieve]
26. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic DZ, Packer M, Clavell AL, Hayes DL, Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAtee P, Messenger J. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002; 346: 18451853.
27. Pina IL, Karalis DG. Comparison of four exercise protocols using anaerobic threshold measurement of functional capacity in congestive heart failure. Am J Cardiol. 1990; 65: 12691271.[CrossRef][Medline] [Order article via Infotrieve]
28. Mezzani A, Corra U, Bosimini E, Giordano A, Giannuzzi P. Contribution of peak respiratory exchange ratio to peak VO2 prognostic reliability in patients with chronic heart failure and severely reduced exercise capacity. Am Heart J. 2003; 145: 11021107.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
M. T. Maeder, P. Ammann, O. D. Schoch, H. Rickli, W. Korte, C. Hurny, J. Myers, and T. Munzer Determinants of Postexercise Heart Rate Recovery in Patients With the Obstructive Sleep Apnea Syndrome Chest, February 1, 2010; 137(2): 310 - 317. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, K. Dickstein, M. Vicenzi, and R. Arena Six-Minute Walk Test and Cardiopulmonary Exercise Testing in Patients With Chronic Heart Failure: A Comparative Analysis on Clinical and Prognostic Insights Circ Heart Fail, November 1, 2009; 2(6): 549 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Parthasarathy, B. Pieske, M. Weisskopf, C. D. Andrews, P. Brunel, A. D. Struthers, and T. M. MacDonald A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction Eur J Heart Fail, October 1, 2009; 11(10): 980 - 989. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Lavie, R. J. Thomas, R. W. Squires, T. G. Allison, and R. V. Milani Exercise Training and Cardiac Rehabilitation in Primary and Secondary Prevention of Coronary Heart Disease Mayo Clin. Proc., April 1, 2009; 84(4): 373 - 383. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Maeder, P. Ammann, and T. Munzer Peak Oxygen Consumption and Heart Rate Recovery in Patients With the Obstructive Sleep Apnea Syndrome Chest, February 1, 2009; 135(2): 584 - 584. [Full Text] [PDF] |
||||
![]() |
G. V. Guimaraes, V. M. d'Avila, P. R. Camargo, L. F. P. Moreira, J. R. L. Luces, and E. A. Bocchi Prognostic value of cardiopulmonary exercise testing in children with heart failure secondary to idiopathic dilated cardiomyopathy in a non-{beta}-blocker therapy setting Eur J Heart Fail, June 1, 2008; 10(6): 560 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cotrufo, L. S. De Santo, A. D. Corte, G. Romano, C. Amarelli, M. De Feo, G. Santarpino, M. Scardone, and G. Nappi Acute hemodynamic and functional effects of surgical ventricular restoration and heart transplantation in patients with ischemic dilated cardiomyopathy. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1054 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Milani, C. J. Lavie, M. R. Mehra, and H. O. Ventura Understanding the Basics of Cardiopulmonary Exercise Testing Mayo Clin. Proc., December 1, 2006; 81(12): 1603 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Haji, F. Cuculi, P. Erne, L. A. Pierard, P. Lancellotti, H. Takagi, T. Kato, Y. Matsuno, S. Stern, A. Abidov, et al. Dyspnea and stress testing. N. Engl. J. Med., February 23, 2006; 354(8): 871 - 873. [Full Text] [PDF] |
||||
![]() |
C. J. Lavie and R. V. Milani Prevalence of Hostility in Young Coronary Artery Disease Patients and Effects of Cardiac Rehabilitation and Exercise Training Mayo Clin. Proc., March 1, 2005; 80(3): 335 - 342. [Abstract] [PDF] |
||||
![]() |
P. J. Hauptman and E. P. Havranek Integrating Palliative Care Into Heart Failure Care Arch Intern Med, February 28, 2005; 165(4): 374 - 378. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |